COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience
Table 3
Management and treatment administered in kidney transplant recipients with COVID-19.
Parameters
Number
Percentage
Treatment parameters
Hospitalization
41
61.2
Domiciliary
26
38.8
Room air management
33
49.3
Oxygen with mask
16
22.9
Noninvasive ventilator
5
7.5
Ventilator
14
20.9
Steroid
67
100
Azithromycin
29
43.3
HCQS
5
7.5
Ivermectin
39
58.2
Doxycycline
37
55.2
Tocilizumab
7
10.4
Remdesivir
23
34.3
Convalescent plasma
22
32.8
Thromboprophylaxis
Anti-platelet
2
3
LMWH
31
45.3
OAC
18
26.9
Anti-nucleoside drugs
Continued
10
14.9
Dose reduced
3
4.5
Drug stopped
51
76.1
Not taking
3
4.5
CNI drugs (tacrolimus or cyclosporine)
CNI continued
48
71.6
CNI dose reduced
1
1.5
CNI stopped
18
26.9
Need for dialysis support (CRRT/SLEDD)
AKI patients needing dialysis
13
20.6
Computerized tomographic scanning with CT score (N = 30)
CT score <10
09
30
CT score 11–14
06
20
CT score ≥15
15
50
ICU requirement
19
28.4
Antibiotics used
41
61.2
Anti-fungal used
18
26.9
HCQS, hydroxy chloroquine sulphate, LMWH, low molecular weight heparin, OAC, oral anti-coagulants, and CNI, calcineurin inhibitors. Patients with advanced graft dysfunction planned/initiated on HD during pandemic before PCR positivity were excluded.
